Intrinsic Activity, 2017; 5 (Suppl. 2): A2.46
doi:10.25006/IA.5.S2-A2.46
From:
2nd International Conference in Pharmacology:
From Cellular Processes to Drug Targets
Rīga, Latvia, 19 – 20 October 2017
MEETING ABSTRACT
Intrinsic Activity,
2017; 5 (Suppl. 2):

Content page
Author index
Keyword index

A2.46
Establishment of the Baltic Biomaterials Centre of Excellence (BBCE)
Maija Dambrova1,*, Elina Makarova1, Arita Dubnika2, Ilze Salma3, Mauro Alini4, Aldo Boccaccini5 and Janis Locs2
  1. Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Latvia
  2. Institute of General Chemical Engineering, Rudolfs Cimdins Riga Biomaterials Innovations and Development Centre, Riga Technical University, Latvia
  3. Department of Oral and Maxillofacial Surgery, Rīga Stradiņš University, Riga, Latvia
  4. AO Research Institute Davos, Switzerland
  5. Institute of Biomaterials, Friedrich-Alexander University of Erlangen-Nuremberg, Germany

* Corresponding author: Maija Dambrova, Latvian Institute of Organic Synthesis, 21 Aizkraukles Str., LV-1006, Riga, Latvia.
e-mail

Background: The ageing population puts a high burden on the society in terms of costs of healthcare and loss of quality of life. The need for bone and joint replacement implants is increasing with older age, and musculo­skeletal conditions are the second-greatest cause of disability globally.

Objectives: The main objective of the BBCE project is to establish the joint Baltic Biomaterials Centre of Excellence focused on the advanced biomaterial development for medical applications. Within the frame of critical-mass formation in research and development, also the cooperation between industry and research organisations will be encouraged, leading to technology transfer and delivery of new products in to the market.

Methods: BBCE will be based on the long-term strategic cooperation and collaboration between AO Research Institute Davos, Switzerland (ARI) and Friedrich-Alexander University of Erlangen-Nuremberg, Germany (FAU) on the one hand and three institutions from Latvia — The Rudolfs Cimdins Riga Biomaterials Innovations and Development Centre of Riga Technical University (RTU RBIDC), the Latvian Institute of Organic Synthesis (LIOS) and Rīga Stradiņš University (RSU) — on the other hand. LIOS will be responsible for the preclinical studies of biomaterials developed by the RTU RBIDC. To consider potential clinical applications, the safety, biocompatibility and biological activity of biomaterials will be assessed in in vitro toxicity tests and in vivo model systems of tissue regeneration.

Conclusions: BBCE will ensure sustainable quality of the research and technology transfer potential in the field of biomaterials for medical applications, mainly focusing on areas possessing the best available scientific and research capacities, in particular, on research of biomaterials, advanced materials, nanotechnology, biomedicine and biopharmacy.

Acknowledgements: This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement no. 763721: BBCE, Baltic Biomaterials Centre of Excellence.

Keywords: biomaterials – medical devices – preclinical studies – excellence centre

open the PDF file

published online:
16 October 2017